The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Relationship of Lipoproteins to Cardiovascular Events
Open accessAbstract
Objectives This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. Background During a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)-lowering therapy did not reduce CV events compared with LDL-C-lowering therapy alone. Methods Subjects taking simvastatin and/or ezetimibe were randomized to receive extended-release (ER) niacin 1,500 to 2,000 mg or minimal immediate-release niacin (≤ 150 mg) as placebo at bedtime. LDL-C levels in both groups were maintained from 40 to 80 mg/dl. Hazard ratios were estimated by using Cox proportional hazards models for relationships between lipoproteins and the composite endpoint of CV death, myocardial infarction, acute coronary syndrome, ischemic stroke, or symptom-driven revascularization. Results CV outcomes were not associated with ER niacin in any baseline lipoprotein tertile. In a subset of patients in both the highest triglyceride (≥ 198 mg/dl) and lowest HDL-C (<33 mg/dl) tertiles, ER niacin showed a trend toward benefit (hazard ratio: 0.74, p = 0.073). In-trial LDL-C levels, non-HDL-C levels, and the total cholesterol/HDL-C ratio were positively associated with CV events in the control group, but these relationships were absent in the ER niacin group. Conclusions Baseline lipoprotein tertiles did not predict differential benefit or harm with ER niacin added to LDL-C-lowering therapy, but a small dyslipidemic subgroup may benefit. ER niacin attenuated expected relationships of lipoprotein risk factors with CV events, raising the possibility that nonlipoprotein actions of niacin could affect risk. (Niacin Plus Statin to Prevent Vascular Events [AIM-HIGH]; NCT00120289).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“subgroup analyses suggested possible benefits to TG lowering in patients with dyslipidemia.5, 6”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, randomized data from large outcome studies across broad populations regarding pharmacological TG lowering and effect on CV outcomes have been mixed (Table 4).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, any benefits to TG‐lowering therapies may be most pronounced among statin‐treated patients in the higher range of TG elevation (ie, ≥200 mg/dL),4, 5, 6 for whom randomized prospectively designed outcome studies have not been previously conducted prior to the REDUCE‐IT study.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“The subgroup data (Table 5) from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid,6 Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM‐HIGH),5 and JELIS4 trials further support a prospective study of EPA in a broader patient population with hypertriglyceridemia, as exemplified in REDUCE‐IT, as a potent”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Clinical and epidemiological studies have demonstrated that triglyceride (TG) elevation is an independent risk factor for increased cardiovascular (CV) events”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Epidemiological, biological, and genetic studies have provided robust evidence of a strong association between elevated TG levels and higher rates of CV events.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
IX. On the problem of the most efficient tests of statistical hypotheses
Neyman, J., & Pearson, E. S. (1933) · Philosophical Transactions of the Royal Society of London Series A Containing Papers of a Mathematical or Physical Character · doi:10.1098/rsta.1933.0009 · Cited by 2,370
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Self-citationClofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
ON THE PROBLEM OF THE MOST EFFICIENT TESTS OF STATISTICAL HYPOTHESES
Neyman, J., & Pearson, E. S. (1967) · University of California Press eBooks · doi:10.1525/9780520339897-008 · Cited by 1,545
Carlson, L. A., & Rosenhamer, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 685
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M. J., Weissman, N. J., & Turco, M. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 638
Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review
Carlson, L. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01528.x · Cited by 591
Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
Albers, J. J., Slee, A. E., O’Brien, K. D., Robinson, J. G., Kashyap, M. L., Kwiterovich, P. O., Xu, P., & Marcovina, S. M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.051 · Cited by 317
Self-citationCarlson, L. A., & Rössner, S. (1978) · Atherosclerosis · doi:10.1016/0021-9150(78)90051-5 · Cited by 315
Lukasova, M., Malaval, C., Gille, A., Kero, J. T., & Offermanns, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci41651 · Cited by 269
Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function
Lee, J. M. S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.036 · Cited by 246
Ganji, S. H., Qin, S., Zhang, L., Kamanna, V. S., & Kashyap, M. L. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.044 · Cited by 236
Self-citationWhitney, E. J., Krasuski, R. A., Personius, B. E., Michalek, J. E., Maranian, A. M., Kolasa, M. W., Monick, E. A., Brown, B. G., & Gotto, A. M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-2-200501180-00008 · Cited by 233
Digby, J. E., Martínez, F. O., Jefferson, A., Ruparelia, N., Chai, J. T., Wamil, M., Greaves, D. R., & Choudhury, R. P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241836 · Cited by 222
[The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus].
Januszkiewicz, Ł. J. (2010) · PubMed · Cited by 216
Lauring, B. P., Taggart, A. K. P., Tata, J. R., Dunbar, R. L., Caro, L., Cheng, K., Chin, J., Colletti, S. L., Côté, J., Khalilieh, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003877 · Cited by 128
Vega, G. L., Cater, N. B., Meguro, S., & Grundy, S. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.01.073 · Cited by 79
Carlson, L. A., Levi, L., & Orö, L. (1968) · Journal of Clinical Investigation · doi:10.1172/jci105869 · Cited by 60
Zhang, L., Kamanna, V. S., Ganji, S. H., Xiong, X., & Kashyap, M. L. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m020917 · Cited by 53
Self-citationImpact of carbohydrate-rich meals on plasma epinephrine levels: dysregulation with aging.
Penev, P., Spiegel, K., Marcinkowski, T., & Van Cauter, E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0415 · Cited by 39
Cited by
Sorted by citations
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 469
Metadata
- Authors
- Guyton, J. R., Slee, A. E., Anderson, T., Fleg, J. L., Goldberg, R. B., Kashyap, M. L., Marcovina, S. M., Nash, S. D., O'Brien, K. D., Weintraub, W. S., Xu, P., Zhao, X.-Q., & Boden, W. E.
- Affiliations
- Duke University (US)
- University of Calgary (CA)
- National Heart, Lung, and Blood Institute (US)
- University of Miami (US)
- University of California, Irvine (US)
- University of Washington (US)
- SUNY Upstate Medical University (US)
- Albany Stratton VA Medical Center Albany (US)
- Corresponding author
- Guyton, John R.
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 62
- Issue
- 17
- Pages
- 1580-1584
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC3862446
- OpenAlex
- W2189339462
- Cited by
- 182
- References
- 23
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 10 · 2023: 6 · 2022: 6 · 2021: 5 · 2020: 15 · 2019: 16 · 2018: 12 · 2017: 15 · 2016: 28 · 2015: 33 · 2014: 22 · 2013: 3
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U01-HL-081616, U01-HL-081649)
- Abbott Laboratories
- Merck & Co.
- Regeneron
- Sanofi US
- Genzyme Corporation, Isis Pharmaceuticals
- Amgen
- Amarin
- GlaxoSmithKline
- Merck
- Roche
- Abbott
- AstraZeneca
- Eli Lilly
- Sanofi
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- nicotinic acid, lipoproteins, cardiovascular events, AIM-HIGH trial, extended-release niacin, low HDL cholesterol, triglycerides, LDL-C lowering therapy, simvastatin, ezetimibe, non-HDL cholesterol, TC/HDL-C ratio, cardiovascular risk prediction
- MeSH terms
- Aged, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Lipoproteins, Cholesterol, HDL, Male, Middle Aged, Niacin, Prospective Studies, Triglycerides, Global Health, Biomarkers, Treatment Outcome, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
